Platelet Rich Plasma: Emerging Role in Orthopaedic Surgery - PowerPoint PPT Presentation

1 / 56
About This Presentation
Title:

Platelet Rich Plasma: Emerging Role in Orthopaedic Surgery

Description:

... Chemotaxis Cell differentiation Angiogenesis Conductive Scaffold Platelet Derived Growth Factor Cell replication Angiogenesis Mitogen for fibroblasts Vascular ... – PowerPoint PPT presentation

Number of Views:1944
Avg rating:3.0/5.0
Slides: 57
Provided by: lucasbade
Category:

less

Transcript and Presenter's Notes

Title: Platelet Rich Plasma: Emerging Role in Orthopaedic Surgery


1
Platelet Rich PlasmaEmerging Role in
Orthopaedic Surgery
  • Lucas J. Bader M.D.
  • Orthopaedic Surgeon
  • Fellowship Trained Foot Ankle Surgeon

2
Disclosure
  • None

3
Goals
  • Definition of PRP
  • Review Basic Science
  • Current Clinical Applications
  • Review of the Literature
  • Future

4
Introduction
  • Emerging field of Biologics
  • PRP utilized and studied since the 1970s
  • Origins in fields of maxillofacial and general
    surgery

5
(No Transcript)
6
(No Transcript)
7
(No Transcript)
8
Definition Platelet Rich Plasma
  • Nonnucleated bodies in peripheral blood
  • Autoglous blood with a concentration of platelets
    above a baseline value
  • Fluid portion of blood

9
Bioactive Factors
  • Potentially enhance healing by delivery of
    various growth factors and cytokines
  • a granules
  • Dense granules

10
a-Granules
  • Cell proliferation
  • Chemotaxis
  • Cell differentiation
  • Angiogenesis
  • Conductive Scaffold

11
Platelet Derived Growth Factor
  • Cell replication
  • Angiogenesis
  • Mitogen for fibroblasts

12
Vascular Endothelial Growth Factor
  • Angiogenesis

13
Transforming Growth Factor-ß1
  • Regulator in balance between fibrosis and myocyte
    regeneration

14
Fibroblast Growth Factor
  • Proliferation of myoblasts,
  • Angiogenesis

15
Epidermal Growth Factor
  • Proliferation of mesenchymal and epithelial cells

16
Hepatocyte Growth Factor
  • Angiogenesis,
  • Mitogen for endothelial cells
  • Antifibrotic

17
Insulin-like growth factor-1
  • Stimulates myoblasts/fibroblasts
  • Mediates growth/repair skeletal muscle

18
(No Transcript)
19
Adhesive Proteins
  • Fibrinogen
  • Fibronectin
  • Vitronectin
  • scaffold

20
(No Transcript)
21
Dense Granules
  • Non-Growth Bioactive Molecules
  • Fundamental effect on the biologic aspects of
    inflammation
  • Cell migration
  • Conductive Matrix

22
Serotonin Histamine
  • Increase capillary permeability
  • Inflammatory cell access
  • Macrophage Activation

23
Adenosine Receptor Activation
  • Modulates inflammation

24
(No Transcript)
25
Advantage
  • Normal biologic ratios vs Exogenous Factors

26
Formulation of PRP
  • Can only be made from anticoagulated blood
  • Cannot be made form clotted whole blood
  • Cannot be made from serum

27
Preparation
  • 30-60 cc Drawn
  • Add citrate to bind ionized calcium and prohibit
    clotting cascade

28
Centrifugation
  • Step 1
  • Red blood cells
  • Leukocytes
  • Platelets
  • Step 2
  • Platelet-Poor Portion
  • Platelet-Rich Portion

29
(No Transcript)
30
Activating Agents
  • Calcium Chloride and/or Thrombin (OR)
  • Collagen (Office)
  • Initiates
  • Platelet activation
  • Clot formation
  • Growth Factor Release

31
Growth Factor Release
  • 70 within 10 minutes
  • Nearly 100 within 1 hr

32
PRP Preparations Systems
  • Several Available
  • Qualitative and Quantitative Variability
  • Volume of autologous blood
  • Centrifuge rate/time
  • Delivery Method
  • Activating Agent
  • Leukocyte concentration (?)
  • Final PRP volume
  • Final Platelet and Growth Factor Concentration

33
(No Transcript)
34
Safety Concerns
  • Autologous Blood
  • Aseptic technique
  • Relative Contraindications
  • Hx of thrombocytopenia
  • Anticoagulant therapy
  • Active infection
  • Tumor
  • Metastatic Disease

35
Cost
  • 150-180 small kits
  • 200 large Kits
  • Centrifuge 1800
  • PRP is currently considered experimental and is
    not reimbursed by most third party payers

36
Effects of PRP on Soft Tissues Bone- Basic
Science
  • 3 phases of healing
  • Inflammation
  • Proliferation
  • Remodeling
  • Basic Metabolic Processes
  • Proliferation
  • Chemotaxis
  • Angiogenesis
  • Differentiation
  • EC Matrix Production

37
Effects PRP on Tendon
  • ?Collagen gene expression
  • ?Vascular endothelial growth factor
  • ?Hepatocyte growth factor
  • ?Matrix Metalloproteinase
  • ?Tendon strength and callus formation
  • ?Cell formation and angiogenesis

38
Effects PRP on Muscle
  • IGF-1 basic FGF improve healing and increase
    fast twitch and tetanus strength
  • Accelerated satellite cell activation
  • Increased diameter of regenerating myofibrils

39
Effects PRP on Bone
  • Stimulate Osteoblasts
  • Stmulate Fibroblasts
  • Up regulate Osteoclacin
  • Encourage differentiation of MSC into bone
    forming cells

40
Further Study
  • Acute injury
  • Chronic injury
  • Timing of injection
  • Effect of serial injections

41
Orthopaedic Applications for PRP
  • Chronic Tendinopathies
  • Bone healing
  • Acute Ligamentous Injuries
  • Muscle injuries
  • Intraoperative Augmentation

42
Chronic Tendinopathy
  • Lateral/medial Epicondylitis
  • Achilles Tendinopathy
  • Patellar Tendinopathy
  • Posterior Tibial Tendinopathy
  • Plantar Fasciitis

43
Bone Healing
  • Fracture Healing
  • Distraction Osteogenesis
  • Osteoarthritis

44
Acute Ligamentous Injury
  • Knee medial collateral ligament
  • Ankle syndesmosis
  • Ankle lateral ligament complex

45
Intraoperative Use
  • Total Knee arthroplasty
  • ACL reconstruction
  • Achilles Tendon Repair
  • Rotator Cuff Repair
  • Acute Articular Cartilage Repair

46
Review of the literature
  • Numerous basic science, animal studies, and small
    case reports
  • Few controlled clinical studies
  • Majority of studies are small, anecdotal, and
    underpowered
  • Non-standardized techniques

47
(No Transcript)
48
Ongoing Positive Effect of Platelet-Rich Plasma
Versus Corticosteroid Injection in Lateral
Epicondylitis A Double-Blind Randomized
Controlled Trial With 2-Year Follow-Up.Gosens T,
Peerbooms JC, van Laar W, den Oudsten BL.
  • Randomized controlled trial Level 1 of evidence
  • PRP group (n 51) or the corticosteroid group (n
    49)
  • PRP group was more often successfully treated
    than the corticosteroid group (P lt .0001).
    Success was defined as a reduction of 25 on VAS
    or DASH scores without a re-intervention after 2
    years.

49
Platelet-Rich Plasma Injection for Chronic
Achilles Tendinopathy A Randomized Controlled
TrialRobert J. de Vos, MD Adam Weir, MBBS Hans
T. M. van Schie, DVM, PhD Sita M. A.
Bierma-Zeinstra, PhD Jan A. N. Verhaar, MD, PhD
Harrie Weinans, PhD Johannes L. Tol, MD, PhD
  • Eccentric exercises (usual care) with either a
    PRP injection (PRP group) or saline injection
    (placebo group)
  • PRP group (n  27) or placebo group (n  27)
  • The mean VISA-A score improved significantly
    after 24 weeks in the PRP group and in the
    placebo group, but the increase was not
    significantly different between both groups

50
Platelet-rich Fibrin Matrix in Arthroscopic
Rotator Cuff Repair A Prospective, Randomized
StudyStephen C Weber, MD Sacramento CA Jeffrey
I Kauffman, MD Sacramento CA
  • Sample size of 30 patients in each group
  • Serial VAS scores were obtained, as well as SST
    scores at each interval. Final scores for each
    group included UCLA and ASES scores.
  • Early follow-up does not show significant
    improvement in perioperative pain or clinical
    outcome.

51
Platelet Rich Plasma (PRP) Effectively Treats
Chronic Achilles TendonosisRaymond R Monto, MD
  • Prospective study of thirty patients
  • No controls
  • AOFAS scores improved to 92 at 6 months.
    Resolution of Achilles abnormalities were seen in
    post treatment MRI/ultrasound studies and 28/30
    were clinically satisfied with their clinical
    results.

52
Literature Summary
  • Greatest support in treating tendinopathy
  • Lateral Epicondylitis
  • Patellar Tendinopathy
  • Achilles Tendinopathy
  • Plantar Fasciitis
  • Caution with Acute Injuries
  • Risk of Fibrosis
  • Return to activity too early

53
Future
  • PRP promising, but not proven
  • Appropriately powered studies
  • Sophisticated models of healing
  • More precise formulations of PRP
  • Narrower indications, but more definitive

54
My Protocol
  • Treatment of last resort prior to surgery
  • Indicated for chronic tendinopathies
  • Performed under ultrasound guidance
  • NSAIDS discontinuation 1 week prior and 2 weeks
    post procedure
  • Activity modification for 7 days

55
(No Transcript)
56
Thanks!
Write a Comment
User Comments (0)
About PowerShow.com